Alcohol use disorder (AUD) has devastating effects, and its prevalence in the US is growing. It is therefore important to examine multiple avenues for successful cessation and continued abstinence. Disulfiram, oral naltrexone, naltrexone IM, and acamprosate are currently the only four medications approved for the treatment of AUD by the FDA. This review aims to examine the efficacy of the...
JAAPASeptember 1, 2024Carolyn F Kundert, Robert M Sobule, Muaid Ithman1 citation
Esketamine, the s(+) enantiomer of ketamine, was approved in 2019 as the first rapid-acting intranasal spray medication for treatment-resistant depression; the drug is given in combination with an antidepressant. The treatment is self-administered in a clinical setting under the supervision of a healthcare provider and usually is well tolerated. Many of its adverse reactions are mild,...
At the time this abstract was written, Elizabeth Boudreau was a student in the Medex Northwest PA program at the University of Washington School of Medicine. Krissa Orlowski is a part-time lecturer in the Medex Northwest PA program. The authors have disclosed no potential conflicts of interest, financial or otherwise.
ABSTRACT: Increasing incidence and survival rates of prostate cancer are leaving more men to suffer the sequelae of their diagnosis and treatment, like depression. Depression and other negative psychosocial factors significantly affect this population but often go undiagnosed and/or ineffectively managed. This case report focuses on the negative effects of prostate cancer diagnosis and...